Vanda Pharmaceuticals Inc
$ 8.17
0.25%
24 Feb - close price
- Market Cap 482,913,000 USD
- Current Price $ 8.17
- High / Low $ 8.55 / 7.72
- Stock P/E N/A
- Book Value 5.54
- EPS -3.74
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.51 %
- 52 Week High 9.60
- 52 Week Low 3.81
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Analyst Target Price
$14.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-05 | 2025-07-31 | 2025-05-07 | 2025-02-13 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-07 | 2023-11-08 | 2023-07-27 | 2023-05-03 |
| Reported EPS | -2.39 | -0.38 | -0.46 | -0.5 | -0.08 | -0.09 | -0.08 | -0.0718 | -0.04 | 0.0024 | 0.03 | 0.06 |
| Estimated EPS | -0.975 | -0.45 | -0.36 | -0.6 | -0.11 | -0.16 | -0.21 | 0.05 | -0.09 | -0.04 | -0.13 | 0.06 |
| Surprise | -1.415 | 0.07 | -0.1 | 0.1 | 0.03 | 0.07 | 0.13 | -0.1218 | 0.05 | 0.0424 | 0.16 | 0 |
| Surprise Percentage | -145.1282% | 15.5556% | -27.7778% | 16.6667% | 27.2727% | 43.75% | 61.9048% | -243.6% | 55.5556% | 106% | 123.0769% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VNDA
2026-02-23 17:35:45
Vanda Pharmaceuticals experienced a significant stock rally following FDA approval for BYSANTI, its new schizophrenia and bipolar I disorder treatment. However, the article suggests this surge might be a short squeeze rather than a reflection of fundamental value, especially since BYSANTI is a "metabolic twin" of an existing drug and the company faces financial concerns and a looming "patent cliff" for other products. Investors are cautioned against chasing the momentum due to the stock's fragility and the company's financial health.
2026-02-23 17:35:45
Vanda Pharmaceuticals (VNDA) surged by 40.1% after the FDA approved BYSANTI (milsaperidone) for the acute treatment of bipolar I disorder and schizophrenia, marking a significant expansion of Vanda's psychiatry franchise. This approval, following NEREUS in December 2025, positions BYSANTI for a Q3 2026 commercial launch with patent protection until 2044. Investors are viewing this as a substantial revenue opportunity.
2026-02-23 15:02:16
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) saw its shares jump over 51% after the FDA approved its drug Bysanti for bipolar I disorder and schizophrenia, with a U.S. launch set for Q3 2026. Despite Q4 2025 earnings losses, robust Fanapt sales indicate future revenue potential, though the company faces a legal investigation related to a previous FDA decision on HETLIOZ. The approval offers a significant boost, but long-term success requires addressing operational inefficiencies and managing ongoing legal scrutiny.
2026-02-23 13:28:55
H.C. Wainwright has increased its price target for Vanda Pharmaceuticals (NASDAQ:VNDA) to $24 from $22, maintaining a Buy rating after the FDA approved the company's Bysanti treatment. Bysanti (milsaperidone) was approved as a first-line therapy for acute manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults. Despite this regulatory success and another recent approval for Nereus, the company reported disappointing Q4 2025 financial results, missing EPS and revenue forecasts.
2026-02-23 13:14:10
Vanda Pharmaceuticals (VNDA) saw its stock jump 44% after the FDA approved its second drug in two months, BYSANTI (milsaperidone), for Bipolar I and Schizophrenia. The drug has patent protection until 2044, preventing generic competition for nearly two decades, and is expected to launch by Q3 2026. This follows the approval of NEREUS in December 2025, and the company is also conducting trials for BYSANTI as a treatment for major depressive disorder.
2026-02-23 13:06:59
Vanda Pharmaceuticals has received FDA approval for its new antipsychotic drug, Bysanti (milsaperidone), for the treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. This approval, following another drug clearance two months prior, strengthens Vanda's psychiatric portfolio. Bysanti is expected to launch in Q3 2026 with patent exclusivity into 2044, supporting Vanda's growth despite current financial performance concerns.
